Changes of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in the serum of patients with autoimmune diseases: association with age and disease activity

References

1 Gartaganis SP, Georgakopoulos CD, Mela EK, Exarchou A, Ziouti N, Assouti M, et al. Matrix metalloproteinases and their inhibitors in exfoliation syndrome. Opthalmic Res 2002; 34:165–71.10.1159/000063661Search in Google Scholar

2 Preston A. Extracellular Matrix Proteases & Proteins Technical Guide. Calbiochem® and Oncogene™ Research Products, 2002.Search in Google Scholar

3 Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 2002; 127:393–8.10.1046/j.1365-2249.2002.01758.xSearch in Google Scholar

4 Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 2001; 125:340–4.10.1046/j.1365-2249.2001.01608.xSearch in Google Scholar

5 Syggelos SA, Eleftheriou SC, Giannopoulou E, Panagiotopoulos E, Aletras A. Gelatinolytic and collagenolytic activity in periprosthetic tissues from loose hip endoprostheses. J Rheumatol 2001; 28:1319–29.Search in Google Scholar

6 Leppä S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 2004; 10:1057–63.10.1158/1078-0432.CCR-03-0047Search in Google Scholar

7 Deutscher MP. One-dimensional gel electrophoresis. In: Deutscher MP, editor. Methods in enzymology. San Diego, CA: Academic Press, 1990;182:425pp.Search in Google Scholar

8 Patron CF, Zouki C, Whittal RM, Chan JSD, Davidge ST, Filep JG. Methods for analysis of matrix metalloproteinase regulation of neutrophil-endothelial cell adhesion. Biol Proced Online 2002; 4:38–48.10.1251/bpo32Search in Google Scholar

9 Ziouti N, Triantaphyllidou IE, Assouti M, Papageorgakopoulou N, Kyriakopoulou D, Anagnostides ST, et al. Solid phase assays in extracellular glycoconjugate research. J Pharm Biomed Anal 2004; 34:771–89.10.1016/S0731-7085(03)00565-XSearch in Google Scholar

10 Murphy G, Koklitis P, Carne AF. Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yields fully active inhibitor. Biochem J 1989; 261:1031–4.10.1042/bj2611031Search in Google Scholar

11 Ribbens C. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis. 2002; 61:161–6.10.1136/ard.61.2.161Search in Google Scholar

12 Zucker S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci 1999; 878:212–27.10.1111/j.1749-6632.1999.tb07687.xSearch in Google Scholar

13 Avolio C, Ruggieri M, Giulani F, Liuzzi GM, Leante R, Riccio P, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003; 136:46–53.10.1016/S0165-5728(03)00006-7Search in Google Scholar

14 Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis. Rheumatology 2002; 41:78–87.10.1093/rheumatology/41.1.78Search in Google Scholar

15 Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, et al. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol 1996; 78:161–71.10.1006/clin.1996.0025Search in Google Scholar

16 Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 6:473–88.Search in Google Scholar

17 Yoshihara Y. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000; 59:455–61.10.1136/ard.59.6.455Search in Google Scholar

18 Perez P. Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjogren’s syndrome. Arthritis Rheum 2000; 43:2807–17.10.1002/1529-0131(200012)43:12<2807::AID-ANR22>3.0.CO;2-MSearch in Google Scholar

19 Molica S, Vitelli G, Levato D, Giannarelli D, Vacca A, Cuneo A, et al. Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur J Haematol 2003; 70:373–8.10.1034/j.1600-0609.2003.00064.xSearch in Google Scholar

20 Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel A, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002; 13:1550–7.10.1093/annonc/mdf270Search in Google Scholar

21 Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem 2003; 49:339–40.10.1373/49.2.339Search in Google Scholar

22 Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001; 314:241–4.10.1016/S0009-8981(01)00679-9Search in Google Scholar

23 Makowski GS, Ramsby ML. Use of citrate to minimize neutrophil matrix metalloproteinase-9 (MMP-9) in human plasma. Anal Biochem 2003; 322:283–6.10.1016/j.ab.2003.07.030Search in Google Scholar

24 Makowskia GS, Ramsby ML. Zymographic analysis of latent and activated forms of matrix metalloproteinase-2 and -9 in synovial fluid: correlation to polymorphonuclear leukocyte infiltration and in response to infection. Clin Chim Acta 2003; 329:77–81.10.1016/S0009-8981(03)00015-9Search in Google Scholar

25 Toubi E, Kessel A, Grushko G, Sabo E, Rozenbaum M, Rosner I. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 2002; 20:221–4.Search in Google Scholar